introduction
Ovarian cancer is the leading cause of death from gynecological cancer in the Western World [1] . Despite adequate management of advanced ovarian cancer with upfront surgery and paclitaxel-carboplatin-based chemotherapy, ∼75% of patients will relapse within the first 3 years [2] . Unfortunately, recurrent ovarian cancer is an incurable disease in the great majority of cases. However, there are several options that can help, not only for palliation, but also for prolonging progression-free interval and even overall survival (OS).
Several factors must be considered when designing the strategy for dealing with recurrent ovarian cancer in every individual case. The most relevant factors are progression-free interval since the last platinum administration in front-line therapy, the number and sites of relapsed disease, the clinical situation of the patient, residual toxicity from previous therapy, and patient preferences and expectations. Patient's hopes were explored in a recent European survey where patients with recurrent ovarian cancer were asked to fill out a questionnaire [3] . The three most common answers were the following: 'no recurrence of tumor-related symptoms' (35%), 'complete healing without any further complication' (28%), and 'live longer than I otherwise would' (24%). Additionally, the last ovarian cancer consensus conference highlighted the importance of secondary end points such as health-related quality of life, patient-reported outcomes, and time without symptoms or toxicity, especially for patients with early relapse ( progression-free interval since last line of platinum of <6 months) [4] .
when should therapy be started?
Some patients present with an elevation of CA 125 that can be detected several months before symptoms or signs occur, or before the disease can be detected by imaging. For a long time, there was a dilemma on how to treat these patients. It was believed that an early treatment based only on an elevated CA 125 would affect the outcome, assuming that treating lowvolume disease with chemotherapy might lead to better survival. However, systemic therapy may cause harmful side-effects that may not be worth suffering if there would be no impact on survival.
The MRC OV05/EORTC 55955 collaborative trial was designed with the aim to establish beneficial effects of early treatment based on an increase of CA125 only compared with delayed treatment based on clinical evidence of a recurrence [5] . One thousand four hundred forty-two patients were registered in the trial, of whom 529 were randomly assigned to early therapy (265 patients) or delayed therapy based on signs or symptoms of disease (264 patients); both were treated according to local practice in each center. The primary end point of this trial was OS. The final analysis showed no difference in survival between early or delayed treatment [hazard ratio (HR) 0.98, 95% confidence interval (CI) 0.80-1.20, P = 0.85]. Median survival from randomization was 25.7 months (95% CI 23.0-27.9) for patients on early treatment and 27.1 months (95% CI 22.8-30.9) for those on delayed treatment. Moreover, early treatment was associated with an early deterioration of quality of life.
The outcome of the trial was accepted in the 4th Ovarian Cancer Consensus Conference (OCCC), in that the participants confirmed and stated that treating patients with an asymptomatic CA-125 increase did not improve OS. However, at the same time, it was stated that asymptomatic patients without radiologic evidence of disease who meet the GCIG definition of CA-125 progression could be eligible for specific clinical trials [4] .
update on randomized trials in early relapse
According to the 4th OCCC early relapse includes patients with progression while receiving last line of platinum-based therapy or within 4 weeks of last platinum dose to those with a progression-free interval since last line of platinum (treatment) of <6 months. This is the population with the worst prognosis and the expected median OS is usually <12 months. For this reason, controlling symptoms without significant side-effects and quality of life must be the main objectives for the treatment of patients with early relapse.
A few trials showed that even moderately active chemotherapy prolongs OS in comparison to nonactive chemotherapy [6, 7] . Several randomized clinical trials have compared polychemotherapy with monotherapy in patients with early relapse of ovarian cancer [8] [9] [10] [11] [12] . However, none of these trials have shown significant differences in time-toprogression or OS (Table 1) . Moreover, toxicity was substantially higher with the combinations, especially hematological toxicity. As quality of life is the main end point in this poor prognostic population, the treatment of patients with this so-called platinum-resistant disease should be based on sequential monotherapy.
Several single agents have shown modest but unequivocal activity in platinum-resistant disease [13] [14] [15] [16] [17] [18] [19] . Response rates of 10%-15% and median OS figures of 9-12 months have been reported in randomized clinical trials with paclitaxel, topotecan, pegylated liposomal doxorubicin (PLD), oxaliplatin, gemcitabine, docetaxel, trabectedine, and etoposide. However, no randomized trial has shown any single agent to be superior in this clinical situation (Table 2) , and selection of the therapeutic agent should be based on the expected toxicity of the available drug, the convenience of administration, and the preference of the patient.
Early relapse ovarian cancer is the optimal field for testing new agents, and patients in a good clinical condition should be offered to participate in such clinical trials. One of the most promising new generations of trials has tested the value of antiangiogenic therapy in this scenario. Bevacizumab, a monoclonal antibody against vascular endothelial growth factor showed clear activity in phase II trials for patients with recurrent disease. Its value in early relapse disease was explored in the AURELIA trial, a randomized phase III trial evaluating bevacizumab 15 mg/kg every 3 weeks plus standard chemotherapy selected by the physician versus the same chemotherapy alone [20] . This trial provides evidence that adding bevacizumab to standard chemotherapy leads to a statistically significant and clinically meaningful improvement in progression-free survival (PFS: 6.7 versus 3.4 months; HR 0.48; 95% CI 0.38-0.60) and objective response rate (ORR) versus chemotherapy alone (30.9% versus 12.6%). This is the first phase III trial in patients with early relapse to show benefit with a targeted therapy and improved outcome with a combination versus monotherapy.
update on randomized trials in late relapse
Late relapse refers to patients with a progression-free interval longer than 6 months after the last dose of platinum-based chemotherapy. The 4th OCCC identified two different groups of patients, those with a progression-free interval of 6-12 months (also called partially platinum-sensitive) and those with a progression-free interval longer than 12 months (also called fully platinum-sensitive).
Two large phase III trials, ICON-4 and AGO OVAR 2.5, and one small randomized phase II trial confirmed the superiority of platinum-based chemotherapy over monotherapy with platinum in patients with a late relapse (>6 months) in terms of response rate and PFS [21] [22] [23] . Additionally, the ICON-4 trial also showed a benefit in OS (Table 3) . A meta-analysis of individual patient data of the two phase III and two randomized phase II trials confirmed the benefit in PFS (HR 0.68; 95% CI 0.57-0.81) and OS (HR 0.8; 95% CI 0.64-1.00) for the combination. Additionally, this meta-analysis confirmed the benefit for the combination in different subgroups of patients Subgroup analysis of the study OVA-301.
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independent of previous use of paclitaxel, the platinum-free interval (6-12 versus >12 months), and the number of previous chemotherapy lines (1 versus 2 or more) [24] . As mentioned above, the paclitaxel-carboplatin combination is inducing a survival benefit over the use of carboplatin alone in this platinum-sensitive subpopulation. However, the almost universal alopecia and grade 2-3 peripheral neuropathy, affecting 20%-30% of the patients, have a negative impact on quality of life. Therefore, other carboplatin-based doublets have been designed with the aim to avoid the paclitaxel-associated toxicity. Gemcitabine, PLD and topotecan have been the selected partners for carboplatin. The CALYPSO trial was a randomized phase III noninferiority trial that showed the PLD/carboplatin combination to be as effective as the paclitaxel-carboplatin but with a different toxicity profile, which consisted of less alopecia and neuropathy but more grade 3-4 thrombocytopenia, mucositis, and hand-foot syndrome [25] . An updated assessment of this trial has confirmed a similar median OS in both arms (33 months with paclitaxelcarboplatin and 30.7 months with carboplatin-PLD) [26] . The HECTOR trial explored the combination of carboplatin and topotecan versus other carboplatin-doublets and showed no significant difference in outcome but a lower hematological toxicity for the experimental arm [27] .
In summary, no carboplatin-doublet can be considered superior to the other in terms of efficacy and the choice between treatment options should be based on toxicity profile and preference of the patient. There are two other strategies beyond carboplatin-based chemotherapy that have demonstrated benefit for patients with a late relapse, i.e. the use of a nonplatinum-based combination, and the addition of the antiangiogenic agent bevacizumab.
The OVA-301 trial tested the combination of trabectedin with PLD against PLD monotherapy in patients who were no candidate or not willing to receive additional platinum-based therapy at relapse. Trabectedin/PLD provided a 21% risk reduction for progressive disease or death compared with PLD monotherapy (HR 0.79; 95% CI 0.65-0.96; P = 0.0190) by independent radiology review [12] . Median PFS was 7.3 months for trabectedin/PLD and 5.8 months for PLD alone. By subgroup analysis, trabectedin/PLD only improved PFS in platinum-sensitive patients (9.2 versus 7.5 months), with a 27% risk reduction (HR 0.73; 95% CI 0.56-0.95; P = 0.0170), and no significant difference was observed in platinum-resistant patients (median, 4.0 and 3.7 months with combination and monotherapy, respectively). An update of the OS data confirmed a trend toward better OS for the combination arm that did not reach statistical significance [28] .
One interesting subanalysis showed that the group of patients with a progression-free interval of 6-12 months obtained an increment in OS when treated with trabectedin and PLD compared with PLD monotherapy [29] . This difference was more evident when platinum was the next regimen used after progression on the trial medication, raising the hypothesis that a prolongation of the platinum-free interval by a nonplatinumbased regimen could restore platinum sensitivity and be beneficial for the patient [30] . This hypothesis is the background of the randomized clinical trial INternational OVArian Cancer Patients Trial With YONdelis (INOVATYON), which includes patients with recurrent OC and a progressionfree interval of 6-12 months after first-line treatment and compares the combination of carboplatin-PLD followed by the regimen selected by the investigator at progression or trabectedine-PLD followed by a platinum-based regimen at progression.
The OCEANS trial tested the addition of bevacizumab to a standard carboplatin doublet for the treatment of patients with a late relapse. This randomized clinical trial compared carboplatin-gemcitabine plus bevacizumab with carboplatingemcitabine-placebo in 484 patients with a recurrent ovarian cancer over 6 months after first line of platinum-based chemotherapy. Patients included needed to have measurable disease and the primary end point was PFS determined by RECIST progression. The association of bevacizumab increased the median PFS from 8.4 to 12.4 months (HR 0.48; 95% CI 0.34-0.60), and was confirmed by an independent radiology committee [31] . Additionally, the response rate was also higher (78.5% versus 57.4%; P < 0.0001). The third preplanned analysis of OS has not shown significant differences (33.4 with bevacizumab versus 33.7 with placebo), which most probably was due to the long postprogression time and the substantial number of chemotherapy lines given during that period.
conclusion
The treatment of patients with recurrent ovarian cancer is still a great challenge for the physician, as several factors have to be considered when selecting a regimen or a strategy, including the hopes and desires of the patient. This review has updated some of the most relevant phase III randomized clinical trials with chemotherapy and new agents in recurrent disease in order to provide the most recent evidence for available drugs. A well justified choice of single drugs or combination of drugs and treatment strategies (i.e. surgery, prolongation of platinum-free interval, or antiangiogenic therapy) may prolong survival for the individual patient with recurrent ovarian cancer.
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